Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah-Jane Schramm

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Molecular Cancer Therapeutics|June 11, 2011
Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studiesSarah-Jane Schramm, Graham J Mann
Melanoma Research|October 30, 2013
Molecular biomarkers of prognosis in melanoma: how far are we from the clinic?Sarah-Jane Schramm, Alexander M Menzies, Graham J Mann
BMC Systems Biology|December 19, 2014
Network-based biomarkers enhance classical approaches to prognostic gene expression signaturesRebecca L Barter, Sarah-Jane Schramm, Graham J Mann, et al.
BMC Research Notes|October 26, 2013
VAN: an R package for identifying biologically perturbed networks via differential variability analysisVivek Jayaswal, Sarah-Jane Schramm, Graham J Mann, et al.
The Journal of Investigative Dermatology|September 30, 2011
Review and cross-validation of gene expression signatures and melanoma prognosisSarah-Jane Schramm, Anna E Campain, Richard A Scolyer, et al.
Proteomics|October 30, 2013
Molecular interaction networks for the analysis of human disease: utility, limitations, and considerationsSarah-Jane Schramm, Vivek Jayaswal, Apurv Goel, et al.
The Journal of Investigative Dermatology|January 15, 2016
Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic MelanomaKaushala Jayawardana, Sarah-Jane Schramm, Varsha Tembe, et al.
Oncotarget|November 12, 2016
A multi-step classifier addressing cohort heterogeneity improves performance of prognostic biomarkers in three cancer typesEllis Patrick, Sarah-Jane Schramm, John T Ormerod, et al.
International Journal of Cancer|July 1, 2014
Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein informationKaushala Jayawardana, Sarah-Jane Schramm, Lauren Haydu, et al.
Pigment Cell & Melanoma Research|June 7, 2013
Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burdenSarah-Jane Schramm, Simone S Li, Vivek Jayaswal, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Molecular Cancer Therapeutics|June 11, 2011
Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studiesSarah-Jane Schramm, Graham J Mann
Melanoma Research|October 30, 2013
Molecular biomarkers of prognosis in melanoma: how far are we from the clinic?Sarah-Jane Schramm, Alexander M Menzies, Graham J Mann
BMC Systems Biology|December 19, 2014
Network-based biomarkers enhance classical approaches to prognostic gene expression signaturesRebecca L Barter, Sarah-Jane Schramm, Graham J Mann, et al.
BMC Research Notes|October 26, 2013
VAN: an R package for identifying biologically perturbed networks via differential variability analysisVivek Jayaswal, Sarah-Jane Schramm, Graham J Mann, et al.
The Journal of Investigative Dermatology|September 30, 2011
Review and cross-validation of gene expression signatures and melanoma prognosisSarah-Jane Schramm, Anna E Campain, Richard A Scolyer, et al.
Proteomics|October 30, 2013
Molecular interaction networks for the analysis of human disease: utility, limitations, and considerationsSarah-Jane Schramm, Vivek Jayaswal, Apurv Goel, et al.
The Journal of Investigative Dermatology|January 15, 2016
Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic MelanomaKaushala Jayawardana, Sarah-Jane Schramm, Varsha Tembe, et al.
Oncotarget|November 12, 2016
A multi-step classifier addressing cohort heterogeneity improves performance of prognostic biomarkers in three cancer typesEllis Patrick, Sarah-Jane Schramm, John T Ormerod, et al.
International Journal of Cancer|July 1, 2014
Determination of prognosis in metastatic melanoma through integration of clinico-pathologic, mutation, mRNA, microRNA, and protein informationKaushala Jayawardana, Sarah-Jane Schramm, Lauren Haydu, et al.
Pigment Cell & Melanoma Research|June 7, 2013
Disturbed protein-protein interaction networks in metastatic melanoma are associated with worse prognosis and increased functional mutation burdenSarah-Jane Schramm, Simone S Li, Vivek Jayaswal, et al.
Pageof 2